VC: Tobira Therapeutics gains $31M



Tobira Therapeutics gains $31M

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Tobira Therapeutics
Princeton, NJ

$31M
First

Domain Associates and Frazier Healthcare Ventures

Tobira is getting started on its development work with therapies licensed in from Japan's Takeda.

Callisto Pharmaceuticals
Denver, CO

$11.2M
Second

RAB Special Situations (Master) Fund Limited and Absolute Octane Master Fund

The money goes to develop Atiprimod and L-Annamcyin, which are currently in clinical trials, and Guanilib, Callistro's drug for gastrointestinal diseases.

BioProcessors Corporation
Woburn, MA

$10M
Third

LSP BioVentues

The company provides micro-engineered solutions for biopharmaceutical process development applications for the biotechnology and pharmaceutical industries.

Celator Pharmaceuticals
Princeton, NJ

$10M

Associates, Quaker BioVentures, TL Ventures, Ventures West Management, GrowthWorks Capital, the Business Development Bank of Canada and Hearthstone Investment

The funding will be used to support clinical trials as well as advance an active preclinical program.

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.